ROCKET PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included in the signature page)
POWER OF ATTORNEY AND SIGNATURES
Each person whose individual signature appears below hereby constitutes and appoints Gaurav Shah, MD and John Militello, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Gaurav Shah, MD | Chief Executive Officer and Director | February 27, 2024 |
| Gaurav Shah, MD | (Principal Executive Officer) | |
| /s/ John C. Militello | VP, Finance, Senior Controller & Treasurer | February 27, 2024 |
| John C. Militello | (Interim Principal Financial Officer, Principal Accounting Officer) | |
| /s/ Carsten Boess | ||
| Carsten Boess | Director | February 27, 2024 |
| /s/ Pedro Granadillo | ||
| Pedro Granadillo | Director | February 27, 2024 |
| /s/ Gotham Makker, MD | ||
| Gotham Makker, MD | Director | February 27, 2024 |
| /s/ David P. Southwell | ||
| David P. Southwell | Director | February 27, 2024 |
| /s/ Roderick Wong, MD | ||
| Roderick Wong, MD | Director | February 27, 2024 |
| /s/ Naveen Yalamanchi, MD | ||
| Naveen Yalamanchi, MD | Director | February 27, 2024 |
| /s/ Elisabeth Björk | ||
| Elisabeth Björk | Director | February 27, 2024 |
| /s/ Fady Malik | ||
| Fady Malik | Director | February 27, 2024 |
| /s/ R. Keith Woods | ||
| R. Keith Woods | Director | February 27, 2024 |
Index to Consolidated Financial Statements Contents
| Reports of Independent Registered Public Accounting Firm (PCAOB ID 274) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Operations for the Years Ended December 31, 2023, 2022 and 2021 | F-6 |
| Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2023, 2022 and 2021 | F-7 |
| Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2023, 2022 and 2021 | F-8 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, 2022 and 2021 | F-9 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.